Novel weight loss formulation meets with some success in trial

Boston, USA-based Gelesis has announced top-line results from a trial of weight loss candidate Gelesis100.

The company says 58% of adults in the Gelesis100 treatment arm achieved weight loss of 5% or more during the study, compared with 42% for the placebo arm.

20% of the treatment arm lost a tenth of their bodyweight, compared with 12% for placebo.

The study did not meet the other co-primary endpoint of 3% mean difference from placebo.

Gelesis plans to discuss filing with regulatory authorities and if they are supportive, plans to file for approval.

Gelesis100 capsules contain a novel kind of hydrogel which absorbs water and expands, with the aim of inducing a feeling of satiety.